The A.A.O. recommends that adults with no signs or risk factors for eye disease get a comprehensive exam at 40 to establish a ...

The first cell rejuvenation therapy is set to enter clinics, testing if aging cells can be reset to a younger, healthier ...

Vision changes can happen for a number of reasons, some of which are no major cause for concern, such as dry eye or fatigue. But others are serious enough to warrant a trip to the emergency department ...

The eyes may reveal how experiences are recalled, according to new Baycrest research that suggests that shifts in eye movements play a critical role in memory retrieval. The findings offer new insight ...

The eyes may reveal how experiences are recalled according to new Baycrest research that suggests that shifts in eye movements play a critical role in memory retrieval. The findings offer new insight ...

The US Food and Drug Administration (FDA) has approved a Phase 1 clinical trial from Life Biosciences that aims to help certain eye cells act younger and improve vision in glaucoma and related ...

When you go for a walk, how does your brain know the difference between a parked car and a moving car? This seemingly simple distinction is challenging because eye movements, such as the ones we make ...

Imagine fixing your eyesight not with risky surgery or an endless supply of eye drops, but by briefly turning your eye off … and back on. That’s the remarkable hook behind Pop Mech’s latest story, ...

Talking while driving is widely recognized as a major source of distraction, but the specific ways conversation interferes with the earliest stages of visual processing have remained largely unclear.

There is a new FDA-approved eye drop on the market called Vizz. This once-daily, prescription eye drop is said to help combat presbyopia, otherwise known as age-related blurry vision. Drugmaker LENZ ...

Shares of the gene therapy developer rose 12.5% to $9.55 in premarket trading on Monday after the news. Sign up here. Under the deal, MeiraGTx will get an upfront payment of $75 million and ...

(Reuters) -MeiraGTx Holdings has signed a deal with Eli Lilly, potentially worth over $475 million, granting the pharma giant rights to its experimental gene therapy for a rare, inherited disorder ...